Therapeutic effect of transcatheter arterial chemoembolization combined with thalidomide or sorafenib in treatment of unresectable primary liver cancer: a comparative analysis

Zheng Kang; He MengGuo; Wang ZhiXiang

doi:10.3969/j.issn.1001-5256.2016.05.017

Issue 5

May 2016

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2016 > 32(5): 899-903

PDF( 1795 KB)

Therapeutic effect of transcatheter arterial chemoembolization combined with thalidomide or sorafenib in treatment of unresectable primary liver cancer: a comparative analysis

DOI: 10.3969/j.issn.1001-5256.2016.05.017

Department of Hepatobiliary Surgery, 215 Hospital of Nuclear Industry of Shaanxi Province

Published Date: 2016-05-20

Abstract

Abstract

Objective To investigate the therapeutic effect and adverse effects of transcatheter arterial chemoembolization( TACE) combined with thalidomide or sorafenib in the treatment of unresectable primary liver cancer. Methods A total of 102 patients who underwent TACE combined with thalidomide or sorafenib in 215 Hospital of Nuclear Industry of Shaanxi Province from January 2012 to August 2013 were enrolled and divided into TACE- thalidomide group( 49 patients) and TACE- sorafenib group( 53 patients). The short- term outcome,long- term outcome,changes in related indices,and adverse events were evaluated. The independent- samples t- test was applied for comparison of continuous data between groups,and the paired t- test was applied for comparison of continuous data within one group; the chi- square test was applied for comparison of categorical data between groups; the survival curve was used for survival analysis,and the log-rank test was applied for survival comparison. Results The indices of short- term outcome,objective response rate and disease control rate,showed no significant differences between the two groups. The 2- year survival showed a significant difference between the two groups( χ2=4. 692,P = 0. 03). The log- rank test showed that overall survival time and median progression- free survival time showed significant differences between the two groups( χ2= 8. 267 and 6. 896,P = 0. 004 and 0. 009). After treatment,alpha- fetoprotein( AFP) and gamma- glutamyl transpeptidase( GGT) showed significant differences between the two groups( t = 2. 035 and 2. 843,P = 0. 038 and 0. 025). The incidence rates of nausea / vomiting,dizziness / headache,rash / desquamation,and increased blood pressure showed significant differences between the two groups( all P < 0. 05). Conclusion TACE combined with thalidomide has the same short- term therapeutic effect as TACE combined with sorafenib and can improve the patient's long- term outcome and significantly reduce the levels of AFP and GGT,but it has high incidence of nausea / vomiting and dizziness / headache.
- liver neoplasms,
- chemoembolization,therapeutic,
- thalidomide,
- sorafeni

FullText(HTML)

References(19)

References

[1]BHAYANI NH,JIANG Y,HAMED O,et al.Advances in the pharmacologic treatment of hepatocellular carcinoma[J].Curr Clin Pharmacol,2015,10(4):299-304.

[2]GE JB,XU YJ.Internal medicine[M].8th.Beijing:People's Medical Publishing House,2013:429.(in Chinese)葛均波,徐永健.内科学[M].8版.北京:人民卫生出版社,2013:429.

[3]YANG XF,LONG XD.Research advances in recurrence and metastasis of primary liver cancer[J].Henan J Surg,2012,18(2):80-83.(in Chinese)杨显富,龙先德.原发性肝癌复发转移的研究进展综述[J].河南外科学杂志,2012,18(2):80-83.

[4]YE YJ,SHEN ZL,WANG S.Therapeutic concept and strategy of metastatic liver cancer[J].Chin J Oper Proc Gen Surg:Electronic Edition,2014,8(1):26-29.(in Chinese)叶颖江,申占龙,王杉.转移性肝癌的治疗理念和策略[J].中华普外科手术学杂志:电子版,2014,8(1):26-29.

[5]Ministry of Health of the People's Republic of China.Diagnosis,management,and treatment of hepatocellular carcinoma(V2011)[J].J Clin Hepatol,2011,27(11):1141-1159.(in Chinese)中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版)[J].临床肝胆病杂志,2011,27(11):1141-1159.

[6]GAO S,ZHU X,YANG RJ,et al.TACE combined with hepatic arterial infusion chemotherapy using oxaliplatin,5-fluorouracil and folinic acid for intermediate and advanced hepatocellular carcinomas[J].J Intervent Radiol,2012,21(5):377-383.(in Chinese)高嵩,朱旭,杨仁杰,等.TACE联合奥沙利铂、氟尿嘧啶、亚叶酸钙肝动脉化疗治疗中晚期原发性肝癌[J].介入放射学杂志,2012,21(5):377-383.

[7]DING J,DAI X,MENG XY,et al.Research advances in response evaluation criteria in solid tumors[J].Chin J Clin Oncol Rehabil,2015,22(9):1150-1152.(in Chinese)丁婕,戴旭,孟宪运,等.实体瘤疗效评价标准的研究进展[J].中国肿瘤临床与康复,2015,22(9):1150-1152.

[8]LAN CH,WANG CY.Progress of TACE for primary liver cancer[J].Curr Physician,2009,15(23):500-502.(in Chinese)兰春虎,王常友.原发性肝癌TACE治疗进展[J].当代医学,2009,15(23):500-502.

[9]COLOMBO M,SANGIOVANNI A.Treatment of hepatocellular carcinoma:beyond international guidelines[J].Liver Int,2015,35(1):129-138.

[10]LEY AM,CHAU CH,FIGG WD.Structural studies reveal thalidomide's mechanism of action and clinical effects:crystal clear or clearly complexed?[J].Cancer Biol Ther,2015,16(1):19-20.

[11]YU J,LIU F,SUN Z,et al.The enhancement of radiosensitivity in human esophageal carcinoma cells by thalidomide and its potential mechanism[J].Cancer Biother Radiopharm,2011,26(2):219-227.

[12]GIRGIS E,MAHONEY J,DARLING-REED S,et al.Arsenic trioxde enhance the cytotoxic effect of thalidomide in a KG-la human acute mylogenous leukemia cell line[J].Oncol lett,2010,1(3):473-479.

[13]PAN JQ,LU GP,YU ZJ.Thalidomide on anti-tumor research[J].Chin J Cancer Prev Treat,2012,19(7):552-555.(in Chinese)潘骥群,鲁光平,于志坚.沙利度胺抗肿瘤的研究进展[J].中华肿瘤防治杂志,2012,19(7):552-555.

[14]NISHIDA N,KITANO M,SAKURAI T,et al.Molecular mechanism and prediction of sorafenib chemoresistance in human hepatocellular carcinoma[J].Dig Dis,2015,33(6):771-779.

[15]ZHANG HJ,GUO WD.Research advances in sorafenib in treatment of tumors[J].Chin J Clinicians:Electronic Edition,2013,7(1):258-260.(in Chinese)张惠洁,郭卫东.索拉菲尼在肿瘤治疗中的研究进展[J].中华临床医师杂志:电子版,2013,7(1):258-260.

[16]YANG M,QI XS,HAN GH.Sorafenib-related adverse events in treatment of hepatocellular carcinoma[J].J Clin Hepatol,2014,30(3):278-281.(in Chinese)杨曼,祁兴顺,韩国宏.索拉菲尼在肝癌治疗中的不良反应[J].临床肝胆病杂志,2014,30(3):278-281.

[17]CHANG BX,XIN SJ.Recent advances in research on alpha-fetoprotein and its clinical application[J].World Chin J Dig,2010,18(6):576-580.(in Chinese)常彬霞,辛绍杰.甲胎蛋白及其临床应用研究进展[J].世界华人消化杂志,2010,18(6):576-580.

[18]ZENG YL,MAO HN.The relationship between changes and prognosis of serum AFP,AKP,GGT in hepatocellular carcinoma after transcatheter hepatic arterial chemoembolization[J].China Trop Med,2011,11(11):1389-1405.(in Chinese)曾颖玲,毛惠南.血清AFP、AKP和GGT在肝癌化疗栓塞后的改变与预后的关系[J].中国热带医学,2011,11(11):1389-1405.

[19]WAN XH,LU XF.Diagnostics[M].8th ed.Beijing:People's Medical Publishing House,2013:366-372.(in Chinese)万学红,卢雪峰.诊断学[M].8版.北京:人民卫生出版社,2013:366-372.

Relative Articles

[1]	Zhiru WANG, Wenjing ZHAO, Xi CHEN. Effect and mechanism of gallic acid on the proliferation， migration， invasion， and apoptosis of human hepatocellular carcinoma HepG2 cells[J]. Journal of Clinical Hepatology, 2025, 41(3): 493-498. doi: 10.12449/JCH250315
[2]	Junzhe CAI, Songbai LIU, Xiaobin FEI, Peng LIU, Changhao ZHU, Xing WANG, Yaozhen PAN. Effect of ankyrin-repeat domain-containing protein 22 on human hepatoma cells and its mechanism[J]. Journal of Clinical Hepatology, 2024, 40(5): 989-996. doi: 10.12449/JCH240519
[3]	Lina BAI, Ying LIU, Chunxiao TANG, Hongxin PIAO, Zhenhua LIN, Wanshan YANG, Aihua JIN. Mechanism of carrimycin in regulating the biological function of pancreatic cancer cells[J]. Journal of Clinical Hepatology, 2022, 38(12): 2793-2801. doi: 10.3969/j.issn.1001-5256.2022.12.020
[4]	Jianan ZHAO, Jinghua PENG, Ping LIU, Yiyang HU. Effect of Cordyceps polysaccharides on hepatocyte apoptosis induced by tumor necrosis factor-α[J]. Journal of Clinical Hepatology, 2021, 37(6): 1368-1372. doi: 10.3969/j.issn.1001-5256.2021.06.029
[5]	Lu Qian, Cheng Xin, Xia ZhenGuo, Chen Zhong. Effect of proteasome subunit beta type 4 on the proliferation and viability of human liver cancer SMMC7721 cells[J]. Journal of Clinical Hepatology, 2020, 36(3): 592-595. doi: 10.3969/j.issn.1001-5256.2020.03.024
[6]	Wang ZeXin, Guan LiJun, Li JianMing, Wang ZhiChao, Xue MengRuo, Qin XiaoJun. Effect of targeted regulation of the Wnt2 gene by microRNA( microRNA-21) on the proliferation and migration of HepG2 hepatoma cells[J]. Journal of Clinical Hepatology, 2020, 36(4): 803-807. doi: 10.3969/j.issn.1001-5256.2020.04.019
[7]	Xiao ErHui, Ning HuiBin, Kang YueHua, Yin Hui, Ma Li, Mao ZhongShan, Zhao Yan, Shang Jia. Downregulation of miR-196b in regulating the growth and apoptosis of hepatoma cells by targeting nuclear apoptosis-inducing factor 1[J]. Journal of Clinical Hepatology, 2020, 36(10): 2230-2235. doi: 10.3969/j.issn.1001-5256.2020.10.014
[8]	Zhang Yang, Chen ShuYing, Xu GuangRu. Effect of extracellular ubiquitin on the proliferation,invasion,and migration of hepatoma cells[J]. Journal of Clinical Hepatology, 2020, 36(6): 1289-1292. doi: 10.3969/j.issn.1001-5256.2020.06.020
[9]	Zhu YueKun, Zhao XianQi, Wang DaWei, Zhang Wei, Tian MaoLin, Li ZhengTian, Zhao Long, Li Chao, Jiang HongChi. Effect of cyclooxygenase-2 antisense RNA combined with celecoxib on the proliferation and apoptosis of hepatoma cells[J]. Journal of Clinical Hepatology, 2018, 34(12): 2614-2618. doi: 10.3969/j.issn.1001-5256.2018.12.021
[10]	Li YingYing, Zhan LiFen, Ceng ZheChao, Xu Shen. Effect of lobaplatin on proliferation and apoptosis of hepatocellular carcinoma HepG2 cells and related mechanism of action[J]. Journal of Clinical Hepatology, 2018, 34(4): 784-788. doi: 10.3969/j.issn.1001-5256.2018.04.018
[11]	Sha Liang, He JianBo, Li KeZhi, Chen Chuang, Huang Shan, Zhao YinNong, Lian Fang, Wu GuoBin. Influence of specific down-regulation of LKB1 expression on invasion and migration of hepatoma cells[J]. Journal of Clinical Hepatology, 2017, 33(5): 875-879. doi: 10.3969/j.issn.1001-5256.2017.05.016
[12]	Geng YaJun, Li ShuDong, Liu ShenZheng, Ren JianJun, Zhang Tong. Inhibitory effect of microRNA-149-5p in the proliferation and migration of HepG2 and Bel-7402 hepatoma cells[J]. Journal of Clinical Hepatology, 2017, 33(6): 1126-1130. doi: 10.3969/j.issn.1001-5256.2017.06.022
[13]	Zhang ChaoYa, Zhao XiangXuan, Lu ZaiMing, Guo QiYong. Research advances in sorafenib- induced apoptotic signaling pathways in liver cancer cells[J]. Journal of Clinical Hepatology, 2016, 32(4): 816-820. doi: 10.3969/j.issn.1001-5256.2016.04.048
[14]	Pan LiuLan, Jia ShengNan, Ma JingTing, Tai JingHua, Jin ZhenJing. Effect of decoy receptor 3 gene on hepatocyte apoptosis[J]. Journal of Clinical Hepatology, 2016, 32(7): 1330-1333. doi: 10.3969/j.issn.1001-5256.2016.07.023
[15]	Du SenRong, Mao XiaoRong, Xiao Ping, Chen Hong. Effects of PARP-1 inhibitors AG-014699 and AZD2281 on proliferation and apoptosis of human hepatoma cell line HepG2[J]. Journal of Clinical Hepatology, 2015, 31(6): 943-946. doi: 10.3969/j.issn.1001-5256.2015.06.027
[16]	Xu Li, Ma KeXin, Dong Bing, Liu HaiWang, Liu QinLong, Gao ZhenMing, Sun DeGuang, Zhang RiXin, Wang HaiBo, Wang LiMing, Liang Rui. Regulatory effect of miRNAs on apoptosis, migration, and cell cycle of hepatocellular carcinoma cells[J]. Journal of Clinical Hepatology, 2013, 29(7): 554-557.
[17]	Shen Bo, Nie YuQiang. Peroxisome proliferator- activated receptor gamma inhibits liver cancer proliferation and metastasis in vitro[J]. Journal of Clinical Hepatology, 2013, 29(9): 702-706. doi: 10.3969/j.issn.1001-5256.2013.09.018
[18]	Jia XiaoLi, Shi JuanJuan, Feng Ting, Cheng YanAn, Wang Rui, Liu JingKun, Dang ShuangSuo. Effects of guggulsterone on proliferation and apoptosis of HepG2 human hepatocellular carcinoma cells[J]. Journal of Clinical Hepatology, 2013, 29(6): 452-455.
[19]	Tai BoJun, Yao Min, Gu Xing, Shi Yun, Yu DanDan, Chen Jie, Zheng WenJie, Yao DengFu, Lu ShaoLin. Effects of silencing glypican- 3 gene transcription on proliferation and apoptosis of hepatoma cells[J]. Journal of Clinical Hepatology, 2013, 29(11): 863-866. doi: 10.3969/j.issn.1001-5256.2013.10.015
[20]	Qiao ChunPing, Chen YueXiang. Advances in study of the relationship between apoptosis and alcoholic liver disease[J]. Journal of Clinical Hepatology, 2012, 28(5): 386-390.

Supplements(0)

Cited By

Cited by

Periodical cited type(7)

1.	李慧萍，郑雪琴，赵群，唐建江. Ⅲ型前胶原、Ⅳ型胶原、层黏连蛋白和透明质酸酶在诊断肝纤维化程度中的应用. 检验医学与临床. 2019(05): 666-668 .
2.	吴一鸣，高树兴，殷新光. 核素首次通过法测定肝动脉血流指数预测日本血吸虫病肝纤维化程度?. 中国肝脏病杂志(电子版). 2018(02): 49-54 .
3.	柯叶芳，高国生，朱喆，陈必成. 血清腺苷脱氨酶对慢性HBV感染者显著肝纤维化的诊断价值. 临床肝胆病杂志. 2018(04): 760-763 . 本站查看
4.	吴一鸣，高树兴，殷新光. 测定肝动脉血流指数预测血吸虫肝纤维化的临床研究. 世界华人消化杂志. 2018(07): 434-440 .
5.	胡烨，张国. 肝纤维化诊断及其严重程度评估. 实用肝脏病杂志. 2017(01): 13-16 .
6.	王娉娉，杨芬. 生物组织弹性成像方法及其新技术进展. 激光生物学报. 2016(06): 501-508+514 .
7.	牟文倩，李春艳，陈延平. 继发性血色病1例报告. 临床肝胆病杂志. 2016(09): 1789-1790 . 本站查看

Other cited types(4)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2775) PDF downloads(429)

Therapeutic effect of transcatheter arterial chemoembolization combined with thalidomide or sorafenib in treatment of unresectable primary liver cancer: a comparative analysis

DOI: 10.3969/j.issn.1001-5256.2016.05.017